The seed round was led by the UK Innovation & Science Seed Fund to support team expansion and product development.
"X-ray scanners are such a common technology that we don’t often think of them as an area for innovation. But the reality is that the addressable market is huge – far beyond the obvious medical applications, with X-ray equipment critical in a range of sectors from construction to manufacturing. Silveray’s technology could play a key role in bringing the world’s oldest imaging technology into the 21st century."
The Series A round was led by Stage 2 Capital with participation from Samaipata and existing investors.
"Effective pre-employment screening and candidate vetting are critical considerations for business operations, compliance, and risk management. Yet, around the world, these processes are highly manual and often delayed, inaccurate, or incomplete."
The financing round was led by Committed Capital with participation from ACF Investors and angel backers.
"Our aim is to give our team the tools they need to be the best and happiest professional risk advisers they can be, to give clients great information and support, and to give insurers a true and trusted partner. This investment will allow us to accelerate our growth plans, and continue to shake up the world of commercial broking."
The oversubscribed seed round will support staff recruitment and design work for a commercial plant in Scotland.
"Our technology takes a low-value forestry co-product and turns it into essential chemical building blocks, with all manner of applications across the chemical industry and beyond, delivering significant environmental and economic benefits. This investment will enable us to push on and commercialise the technology, and is a fantastic show of support for what we believe to be a world-changing innovation."
The financing round was backed by ACF Investors, o2h Ventures, Jonathan Milner, and R42 Group.
"This latest funding will enable us to build on and accelerate our successful computational design-led discovery focus. We are excited to be playing a pivotal role in the innovation of oncological treatments leading to better outcomes for cancer patients worldwide. Our groundbreaking new approach stands to be initially validated by the proof-of-concept studies. We are achieving rapid progress not only with our industry-leading drug discovery programme, but also our proprietary AI platform. This has led to increasing interest from third parties in our machine learning capabilities, so we are keen to capitalise on this demand and establish a commercial effort in this area"
